drugset / Trial / NCT06542536

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men

NCT06542536 ↗

Phase 1 Completed 73 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in the participants body. Oral monlunabant is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. The participant will either get monlunabant or placebo or a combination of both. Which treatment the participant get is decided by chance. The study will last for about 49 days in total.

Timeline

Start
2024-08-09
Primary completion
2024-10-25
Completion
2024-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Monlunabant Small molecule — Oral

Indications